Health care resource utilization and costs for influenza-like illness among midwestern health plan members

Donald G. Klepser, Carolyn E. Corn, Michael Schmidt, Allison M. Dering-Anderson, Michael E. Klepser

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: Each year, 6%-20% of U.S. residents are infected by influenza, and more than 200,000 people are hospitalized due to complications related to influenza. In 2003, it was estimated that the direct medical costs for the treatment of influenza were $10.4 billion in the United States. OBJECTIVES: To (a) assess the current practice associated with the diagnosis and treatment of influenza-like illnesses (ILIs) in inpatient, ambulatory/ outpatient, and emergency room settings and (b) evaluate how the use of rapid influenza diagnostic tests (RIDTs) impacts patient health care utilization and cost in these clinical settings. METHODS: For this retrospective cohort study, patients with an influenzarelated health care encounter were identified using claims data from a midwestern commercial health insurance plan. In order to select the claims relevant to this study, the corresponding influenza ICD-9-CM codes, GPI codes, and CPT codes for the diagnosis, prescriptions, and procedures were identified and used to detect ILI claims. For the cost analysis of these data, the allowed amount in the billing claims was utilized. Using these data, the median cost, mean cost, minimum cost, and maximum cost were determined for each episode of care. The median costs were compared, and Wilcoxon two-sample tests and Kruskal-Wallis tests with a P value of 0.05 were used as the level of significance. RESULTS: Over 32% of the influenza-like illness episodes identified in this study involved empiric antiviral therapy as either treatment (15%) or prophylaxis (17.1%) without an accompanying medical visit. Of patient episodes with a medical visit, patients with an RIDT for influenza received antiviral treatment in 27.5% of the episodes compared with 55% of the episodes for patients with no RIDT. Episodes with a medical visit and an RIDT had statistically significant (P < 0.001) lower median 30-day influenzarelated health care costs ($62.46) than episodes with a medical visit but no RIDT ($192.83), as well as with empiric therapy but no accompanying medical visit ($105.64). CONCLUSIONS: The results of this analysis for ILI claims over a 2-year period suggest that utilization of RIDTs for influenza may reduce overall influenza-related health care costs and improve proper utilization of antiinfluenza medications.

Original languageEnglish (US)
Pages (from-to)568-573
Number of pages6
JournalJournal of Managed Care Pharmacy
Volume21
Issue number7
StatePublished - Jan 1 2015

Fingerprint

Patient Acceptance of Health Care
Health Resources
Health care
Health Care Costs
Human Influenza
Health
Costs
Routine Diagnostic Tests
Costs and Cost Analysis
Antiviral Agents
Emergency rooms
Health insurance
Current Procedural Terminology
Episode of Care
Therapeutics

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science
  • Health Policy

Cite this

Health care resource utilization and costs for influenza-like illness among midwestern health plan members. / Klepser, Donald G.; Corn, Carolyn E.; Schmidt, Michael; Dering-Anderson, Allison M.; Klepser, Michael E.

In: Journal of Managed Care Pharmacy, Vol. 21, No. 7, 01.01.2015, p. 568-573.

Research output: Contribution to journalArticle

@article{74c79eb1b51b460585bf3c9e8f0b45a4,
title = "Health care resource utilization and costs for influenza-like illness among midwestern health plan members",
abstract = "BACKGROUND: Each year, 6{\%}-20{\%} of U.S. residents are infected by influenza, and more than 200,000 people are hospitalized due to complications related to influenza. In 2003, it was estimated that the direct medical costs for the treatment of influenza were $10.4 billion in the United States. OBJECTIVES: To (a) assess the current practice associated with the diagnosis and treatment of influenza-like illnesses (ILIs) in inpatient, ambulatory/ outpatient, and emergency room settings and (b) evaluate how the use of rapid influenza diagnostic tests (RIDTs) impacts patient health care utilization and cost in these clinical settings. METHODS: For this retrospective cohort study, patients with an influenzarelated health care encounter were identified using claims data from a midwestern commercial health insurance plan. In order to select the claims relevant to this study, the corresponding influenza ICD-9-CM codes, GPI codes, and CPT codes for the diagnosis, prescriptions, and procedures were identified and used to detect ILI claims. For the cost analysis of these data, the allowed amount in the billing claims was utilized. Using these data, the median cost, mean cost, minimum cost, and maximum cost were determined for each episode of care. The median costs were compared, and Wilcoxon two-sample tests and Kruskal-Wallis tests with a P value of 0.05 were used as the level of significance. RESULTS: Over 32{\%} of the influenza-like illness episodes identified in this study involved empiric antiviral therapy as either treatment (15{\%}) or prophylaxis (17.1{\%}) without an accompanying medical visit. Of patient episodes with a medical visit, patients with an RIDT for influenza received antiviral treatment in 27.5{\%} of the episodes compared with 55{\%} of the episodes for patients with no RIDT. Episodes with a medical visit and an RIDT had statistically significant (P < 0.001) lower median 30-day influenzarelated health care costs ($62.46) than episodes with a medical visit but no RIDT ($192.83), as well as with empiric therapy but no accompanying medical visit ($105.64). CONCLUSIONS: The results of this analysis for ILI claims over a 2-year period suggest that utilization of RIDTs for influenza may reduce overall influenza-related health care costs and improve proper utilization of antiinfluenza medications.",
author = "Klepser, {Donald G.} and Corn, {Carolyn E.} and Michael Schmidt and Dering-Anderson, {Allison M.} and Klepser, {Michael E.}",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "21",
pages = "568--573",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "7",

}

TY - JOUR

T1 - Health care resource utilization and costs for influenza-like illness among midwestern health plan members

AU - Klepser, Donald G.

AU - Corn, Carolyn E.

AU - Schmidt, Michael

AU - Dering-Anderson, Allison M.

AU - Klepser, Michael E.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - BACKGROUND: Each year, 6%-20% of U.S. residents are infected by influenza, and more than 200,000 people are hospitalized due to complications related to influenza. In 2003, it was estimated that the direct medical costs for the treatment of influenza were $10.4 billion in the United States. OBJECTIVES: To (a) assess the current practice associated with the diagnosis and treatment of influenza-like illnesses (ILIs) in inpatient, ambulatory/ outpatient, and emergency room settings and (b) evaluate how the use of rapid influenza diagnostic tests (RIDTs) impacts patient health care utilization and cost in these clinical settings. METHODS: For this retrospective cohort study, patients with an influenzarelated health care encounter were identified using claims data from a midwestern commercial health insurance plan. In order to select the claims relevant to this study, the corresponding influenza ICD-9-CM codes, GPI codes, and CPT codes for the diagnosis, prescriptions, and procedures were identified and used to detect ILI claims. For the cost analysis of these data, the allowed amount in the billing claims was utilized. Using these data, the median cost, mean cost, minimum cost, and maximum cost were determined for each episode of care. The median costs were compared, and Wilcoxon two-sample tests and Kruskal-Wallis tests with a P value of 0.05 were used as the level of significance. RESULTS: Over 32% of the influenza-like illness episodes identified in this study involved empiric antiviral therapy as either treatment (15%) or prophylaxis (17.1%) without an accompanying medical visit. Of patient episodes with a medical visit, patients with an RIDT for influenza received antiviral treatment in 27.5% of the episodes compared with 55% of the episodes for patients with no RIDT. Episodes with a medical visit and an RIDT had statistically significant (P < 0.001) lower median 30-day influenzarelated health care costs ($62.46) than episodes with a medical visit but no RIDT ($192.83), as well as with empiric therapy but no accompanying medical visit ($105.64). CONCLUSIONS: The results of this analysis for ILI claims over a 2-year period suggest that utilization of RIDTs for influenza may reduce overall influenza-related health care costs and improve proper utilization of antiinfluenza medications.

AB - BACKGROUND: Each year, 6%-20% of U.S. residents are infected by influenza, and more than 200,000 people are hospitalized due to complications related to influenza. In 2003, it was estimated that the direct medical costs for the treatment of influenza were $10.4 billion in the United States. OBJECTIVES: To (a) assess the current practice associated with the diagnosis and treatment of influenza-like illnesses (ILIs) in inpatient, ambulatory/ outpatient, and emergency room settings and (b) evaluate how the use of rapid influenza diagnostic tests (RIDTs) impacts patient health care utilization and cost in these clinical settings. METHODS: For this retrospective cohort study, patients with an influenzarelated health care encounter were identified using claims data from a midwestern commercial health insurance plan. In order to select the claims relevant to this study, the corresponding influenza ICD-9-CM codes, GPI codes, and CPT codes for the diagnosis, prescriptions, and procedures were identified and used to detect ILI claims. For the cost analysis of these data, the allowed amount in the billing claims was utilized. Using these data, the median cost, mean cost, minimum cost, and maximum cost were determined for each episode of care. The median costs were compared, and Wilcoxon two-sample tests and Kruskal-Wallis tests with a P value of 0.05 were used as the level of significance. RESULTS: Over 32% of the influenza-like illness episodes identified in this study involved empiric antiviral therapy as either treatment (15%) or prophylaxis (17.1%) without an accompanying medical visit. Of patient episodes with a medical visit, patients with an RIDT for influenza received antiviral treatment in 27.5% of the episodes compared with 55% of the episodes for patients with no RIDT. Episodes with a medical visit and an RIDT had statistically significant (P < 0.001) lower median 30-day influenzarelated health care costs ($62.46) than episodes with a medical visit but no RIDT ($192.83), as well as with empiric therapy but no accompanying medical visit ($105.64). CONCLUSIONS: The results of this analysis for ILI claims over a 2-year period suggest that utilization of RIDTs for influenza may reduce overall influenza-related health care costs and improve proper utilization of antiinfluenza medications.

UR - http://www.scopus.com/inward/record.url?scp=84934757232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934757232&partnerID=8YFLogxK

M3 - Article

C2 - 26108381

AN - SCOPUS:84934757232

VL - 21

SP - 568

EP - 573

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 7

ER -